Karen S. Lynch - Feb 2, 2023 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Stock symbol
CVS
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 03:30 PM
Previous filing
Apr 5, 2022
Next filing
Apr 4, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +207K $0.00 207K Feb 2, 2023 Direct F1
holding CVS Common Stock (By Trust) 304K Feb 2, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 172K Feb 2, 2023 Common Stock 172K $101.09 Direct F2
holding CVS Stock Appreciation Rights 193K Feb 2, 2023 Common Stock 193K $45.91 Direct F3
holding CVS Stock Appreciation Rights 94K Feb 2, 2023 Common Stock 94K $37.91 Direct F4
holding CVS Stock Option 242K Feb 2, 2023 Common Stock 242K $54.19 Direct F5
holding CVS Stock Option 211K Feb 2, 2023 Common Stock 211K $58.34 Direct F6, F7
holding CVS Stock Option 225K Feb 2, 2023 Common Stock 225K $74.30 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on August 31, 2020. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 2, 2023.
F2 Option becomes exercisable in four equal installments, commencing 4/1/2023.
F3 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F4 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F6 The number of shares subject to the option were calculated using a 30-day average price.
F7 Option became exercisable in four equal installments, commencing 4/1/2021.
F8 Option became exercisable in four equal installments, commencing 4/1/2022.